NLRP3/NALP3 Antibody (25N10E9) [Janelia Fluor® 549]

• Reactivity: Mu
• Applications: WB
• Clone: 25N10E9
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Janelia Fluor 549

NLRP3/NALP3 Antibody (25N10E9) [Janelia Fluor® 549] Summary

• Description: This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
  
  For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
• Immunogen: A recombinant protein corresponding to the NOD domain of murine NLRP3/NALP3 Antibody (25N10E9) (amino acids 216-385) was used as the immunogen for this antibody.
• Specificity: The epitope that 25N10E9 binds to the NOD region of NLRP3/NALP3 has not been mapped.
• Isotype: IgG2b Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: NLRP3
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Western Blot
• Application Notes: Recommended applications are based on validated applications from the unconjugated base product NBP2-03948. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein G purified

Notes

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

Alternate Names for NLRP3/NALP3 Antibody (25N10E9) [Janelia Fluor® 549]

• AGTAVPRL
• AII
• AII/AVP
• Angiotensin/vasopressin receptor AII/AVP-like
• AVP
• C1orf7
• Caterpiller protein 1.1
• CIAS1
• CLR1.1
• Cold autoinflammatory syndrome 1 protein
• Cold autoinflammatory syndrome 1
• Cryopyrin
• Familial cold autoinflammatory syndrome
• FCAS
• FCU
• Leucine-rich repeat-, and PYD-containing protein 3
• Muckle-Wells syndrome
• MWS
• NACHT
• NACHT, LRR and PYD containing protein 3
• NACHT, LRR and PYD domains-containing protein 3
• NALP3
• NLR family, pyrin domain containing 3
• NLRP3
• Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And Pyrin Domain Containing 3
• PYPAF1
• PYRIN-containing APAF1-like protein 1

Background

NACHT, LRR and PYD domains-containing protein 3 (NALP3), Nucleotide-Binding Oligomerization Domain, or Leucine Rich Repeat and Pyrin Domain Containing 3 (NLRP3) (human NLRP3-isoform 2 theoretical molecular weight 118kDa) acts as a cytosolic receptor for stress-signals initiated by a wide variety of pathogen-associated molecular patterns (PAMPS) and danger-associated molecular patterns (DAMPs) (1). NLRP3 belongs to the family of NOD-like receptors, a type of pattern-recognition receptor (PRR) which participates in innate immune responses. The exact mechanisms leading to NLRP3 activation are still not fully resolved. Some proposed mechanisms for NLRP3 inflammasome activation include induced ion channel flux as exemplified by potassium efflux, sodium influx and calcium signaling, generation of mitochondrial reactive oxygen species (ROS), and lysosomal destabilization (2). Activation of NLRP3 induces its association with the adaptor protein Apoptosis-associated Speck-like protein containing CARD (ASC) forming a complex that binds to Caspase-1 (1, 2). The inflammasome complex, comprised of NLRP3, ASC and Caspase 1, induces the processing of pro-IL-1beta and pro-IL-18 and release of the mature inflammatory cytokines IL-1beta and IL-18 and pyroptosis (1-3).

NLRP3 is expressed in a variety of cell types such as monocytes, dendritic cells, lymphocytes and epithelial cells (3). Abnormal NLRP3 activation may occur as the result of inherited mutations and is associated with diseases such as hereditary periodic fevers (HPFs) and familial cold autoinflammatory syndrome (FCAS). Additionally, abnormal NLRP3 activation is associated with a variety of diseases such as gout, obesity, atherosclerosis, Alzheimers, multiple sclerosis and type 2 diabetes (1, 3). NLRP3 inflammasome is regulated by several post-translational modifications (e.g., ubiquitination, phosphorylation and sumoylation) as well as by various interacting proteins (e.g., JNK1, FBXO3, TXNIP, MARK4 and PKD) (4).

References

1. Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015). NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biology. https://doi.org/10.1016/j.redox.2015.01.008

2. Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death and Disease. https://doi.org/10.1038/s41419-019-1413-8

3. Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019). Pharmacological inhibitors of the nlrp3 inflammasome. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02538

4. Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20133328

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for NLRP3/NALP3 Antibody (NBP2-03948JF549). (Showing 1 - 3 of 3 FAQ).

1. Are the NLRP3/NALP3 antibodies validated in Simple Western?
   • Yes, we offer a NLRP3/NALP3 antibody that have been tested in Simple Western: NBP2-03948.
2. Does NLRP3/NALP3 antibodies come in lyophilized form?
   • Yes, we carry 3 NLRP2 antibodies in lyophilized format: AF6789, AF7010, MAB6789, MAB7578.
3. What is the theoretical molecular weight for NLRP3/NALP3 antibodies?
   • The TMW of NLRP3/NALP3 antibodies is approximately 118 kDa.

Bioinformatics

• Gene Symbol: NLRP3